TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Serious Adverse Reactions
Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.
Immune-Mediated Pneumonitis
Immune-Mediated Hepatitis
Immune-Mediated Colitis
Immune-Mediated Endocrinopathies
Other Immune-Mediated Adverse Reactions
Infections
Infusion-Related Reactions
Embryo-Fetal Toxicity
Nursing Mothers/Fertility
Most Common Adverse Reactions
The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with bevacizumab for HCC were hypertension (30%), fatigue/asthenia (26%), and proteinuria (20%).
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see full TECENTRIQ Prescribing Information and full Avastin Prescribing Information for additional Important Safety Information.